Search

everythinglearnresearchcommunity

for

Search:↓

Triptolide effectively and safely reduces actinic keratosis lesions in mice.

Vinblastine can help treat childhood ITP but may cause reversible side effects.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Erlotinib can cause nonscarring hair loss and itchy skin.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Ruxolitinib can help regrow hair in severe alopecia areata.

Oral tofacitinib successfully treated a girl's severe skin and hair conditions.

JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Deleting Smad4 and PTEN genes in mice causes rapid, invasive forestomach cancer.

The FDA approved a new Pfizer drug for hair loss in teens.

Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

Stopping gefitinib improved scalp condition in a woman with lung cancer.

Gefitinib therapy can cause unusual hair growth on the nose.